<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35140498</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1178-7031</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>15</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Journal of inflammation research</Title>
          <ISOAbbreviation>J Inflamm Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Nrf2 Inhibits the Progression of Parkinson's Disease by Upregulating AABR07032261.5 to Repress Pyroptosis.</ArticleTitle>
        <Pagination>
          <StartPage>669</StartPage>
          <EndPage>685</EndPage>
          <MedlinePgn>669-685</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.2147/JIR.S345895</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Parkinson's disease (PD) is associated with dysregulated neural cell death, such as pyroptosis, but its regulatory mechanisms are poorly understood. This study investigated roles of nuclear factor E2-related factor 2 (Nrf2) in regulating pyroptosis and PD development.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Cellular and rat PD models established by 6-OHDA exposure were subjected to Nrf2 overexpression. Neurobehavioral functions were assessed by the traction test, Morris Water Maze, and open field test. Cell proliferation was analyzed by MTS assay, while flow cytometry was applied to quantify levels of reactive oxygen species (ROS) and apoptosis. Nissl bodies in rat brains were detected by Nissl staining, and cell apoptosis in brain tissues was assessed by terminal deoxynucleotidyl transferase dUTP nick-end labeling. Differential expression of lncRNA and mRNA was characterized by deep sequencing.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A cellular PD model was successfully established by inducing PC12 cell differentiation with nerve growth factor-β and exposing differentiated cells to 6-OHDA. Cells exhibited significantly increased ROS levels, enhanced pyroptosis, and inhibited Nrf2 phosphorylation. The rat PD model exhibited impaired muscle strength, increased pyroptosis, and repressed Nrf2 phosphorylation. Nrf2 overexpression effectively repressed pyroptosis in both cellular and rat PD models. Marked alterations of lncRNA and mRNA profiles were induced by Nrf2 overexpression in the cellular PD model, which involved multiple signaling pathways. Silencing of the lncRNA AABR07032261.5 significantly promoted pyroptosis in the cellular PD model.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nrf2 suppressed PD pathogenesis in cellular and animal models by promoting AABR07032261.5, which repressed pyroptosis.</AbstractText>
          <CopyrightInformation>© 2022 Zhong et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhong</LastName>
            <ForeName>Yunxiao</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510600, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Cai</LastName>
            <ForeName>Xiaodong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510655, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Ding</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liao</LastName>
            <ForeName>Jinchi</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0002-2327-769X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510600, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Xu</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510600, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Yiying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510600, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xiaohong</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510600, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Long</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510600, People's Republic of China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Inflamm Res</MedlineTA>
        <NlmUniqueID>101512684</NlmUniqueID>
        <ISSNLinking>1178-7031</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AABR07032261.5</Keyword>
        <Keyword MajorTopicYN="N">Nrf2</Keyword>
        <Keyword MajorTopicYN="N">Parkinson’s disease</Keyword>
        <Keyword MajorTopicYN="N">lncRNAs</Keyword>
        <Keyword MajorTopicYN="N">oxidative stress</Keyword>
        <Keyword MajorTopicYN="N">pyroptosis</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>10</Day>
          <Hour>5</Hour>
          <Minute>33</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35140498</ArticleId>
        <ArticleId IdType="pmc">PMC8818975</ArticleId>
        <ArticleId IdType="doi">10.2147/JIR.S345895</ArticleId>
        <ArticleId IdType="pii">345895</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386:896–912. doi:10.1016/s0140-6736(14)61393-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(14)61393-3</ArticleId>
            <ArticleId IdType="pubmed">25904081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raza C, Anjum R, Shakeel NUA. Parkinson’s disease: mechanisms, translational models and management strategies. Life Sci. 2019;226:77–90. doi:10.1016/j.lfs.2019.03.057</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lfs.2019.03.057</ArticleId>
            <ArticleId IdType="pubmed">30980848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15:1257–1272. doi:10.1016/s1474-4422(16)30230-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1474-4422(16)30230-7</ArticleId>
            <ArticleId IdType="pubmed">27751556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612. doi:10.3389/fnins.2018.00612</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2018.00612</ArticleId>
            <ArticleId IdType="pmc">PMC6125353</ArticleId>
            <ArticleId IdType="pubmed">30214392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puschmann A. New genes causing hereditary Parkinson’s disease or Parkinsonism. Curr Neurol Neurosci Rep. 2017;17:66. doi:10.1007/s11910-017-0780-8</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11910-017-0780-8</ArticleId>
            <ArticleId IdType="pmc">PMC5522513</ArticleId>
            <ArticleId IdType="pubmed">28733970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson’s disease. Aging Cell. 2019;18:e13031. doi:10.1111/acel.13031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/acel.13031</ArticleId>
            <ArticleId IdType="pmc">PMC6826160</ArticleId>
            <ArticleId IdType="pubmed">31432604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson’s disease. Mol Brain. 2017;10:53. doi:10.1186/s13041-017-0340-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13041-017-0340-9</ArticleId>
            <ArticleId IdType="pmc">PMC5706368</ArticleId>
            <ArticleId IdType="pubmed">29183391</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong H, Hao L, Li X, Wang C, Wu X. Anti-inflammatory role of trilobatin on lipopolysaccharide-induced acute lung injury through activation of ampk/gsk3β-nrf2 pathway. Signa Vitae. 2020;16:160–166.</Citation>
        </Reference>
        <Reference>
          <Citation>Morris G, Walker AJ, Berk M, Maes M, Puri BK. Cell death pathways: a novel therapeutic approach for neuroscientists. Mol Neurobiol. 2018;55:5767–5786. doi:10.1007/s12035-017-0793-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12035-017-0793-y</ArticleId>
            <ArticleId IdType="pmc">PMC5994217</ArticleId>
            <ArticleId IdType="pubmed">29052145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frank D, Vince JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk. Cell Death Differ. 2019;26:99–114. doi:10.1038/s41418-018-0212-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-018-0212-6</ArticleId>
            <ArticleId IdType="pmc">PMC6294779</ArticleId>
            <ArticleId IdType="pubmed">30341423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S, Yuan YH, Chen NH, Wang HB. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. Int Immunopharmacol. 2019;67:458–464. doi:10.1016/j.intimp.2018.12.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.intimp.2018.12.019</ArticleId>
            <ArticleId IdType="pubmed">30594776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de la Vega MR, Chapman E, Zhang DD. NRF2 and the Hallmarks of cancer. Cancer Cell. 2018;34:21–43. doi:10.1016/j.ccell.2018.03.022</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.03.022</ArticleId>
            <ArticleId IdType="pmc">PMC6039250</ArticleId>
            <ArticleId IdType="pubmed">29731393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29:1727–1745. doi:10.1089/ars.2017.7342</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/ars.2017.7342</ArticleId>
            <ArticleId IdType="pmc">PMC6208165</ArticleId>
            <ArticleId IdType="pubmed">28899199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cell Mol Life Sci. 2016;73:3221–3247. doi:10.1007/s00018-016-2223-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-016-2223-0</ArticleId>
            <ArticleId IdType="pmc">PMC4967105</ArticleId>
            <ArticleId IdType="pubmed">27100828</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammal Kaidery N, Ahuja M, Thomas B. Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson’s disease. Mol Cell Neurosci. 2019;101:103413. doi:10.1016/j.mcn.2019.103413</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mcn.2019.103413</ArticleId>
            <ArticleId IdType="pmc">PMC6981291</ArticleId>
            <ArticleId IdType="pubmed">31644952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao MW, Yang P, Zhao LL. Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181/SIRT1/PGC-1alpha/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells: implication for association between chlorpyrifos and Parkinson’s disease. Environ Toxicol. 2019;34:699–707. doi:10.1002/tox.22736</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/tox.22736</ArticleId>
            <ArticleId IdType="pubmed">30835941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rostamian Delavar M, Baghi M, Safaeinejad Z, et al. Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson’s disease. Gene. 2018;662:54–65. doi:10.1016/j.gene.2018.04.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2018.04.010</ArticleId>
            <ArticleId IdType="pubmed">29631008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Y, Jiang Y, He Y, et al. Vina-ginsenoside R4 from panax ginseng leaves alleviates 6-OHDA-induced neurotoxicity in PC12 cells via the PI3K/Akt/GSK-3β signaling pathway. J Agric Food Chem. 2020;68:15239–15248. doi:10.1021/acs.jafc.0c06474</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jafc.0c06474</ArticleId>
            <ArticleId IdType="pubmed">33290066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghahari L, Safari M, Rahimi Jaberi K, et al. Mesenchymal stem cells with granulocyte colony-stimulating factor reduce stress oxidative factors in Parkinson’s disease. Iran Biomed J. 2020;24:89–98. doi:10.29252/ibj.24.2.89</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.29252/ibj.24.2.89</ArticleId>
            <ArticleId IdType="pmc">PMC6984711</ArticleId>
            <ArticleId IdType="pubmed">31677610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J, Dai X, Zhou L, Li X, Pan D. Edaravone plays protective effects on LPS-induced microglia by switching M1/M2 phenotypes and regulating NLRP3 inflammasome activation. Front Pharmacol. 2021;12:691773. doi:10.3389/fphar.2021.691773</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2021.691773</ArticleId>
            <ArticleId IdType="pmc">PMC8201503</ArticleId>
            <ArticleId IdType="pubmed">34135761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boccella S, Iannotta M, Cristiano C, et al. Treatment with 2-pentadecyl-2-oxazoline restores mild traumatic brain injury-induced sensorial and neuropsychiatric dysfunctions. Front Pharmacol. 2020;11:91. doi:10.3389/fphar.2020.00091</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.00091</ArticleId>
            <ArticleId IdType="pmc">PMC7052365</ArticleId>
            <ArticleId IdType="pubmed">32161542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y, Cui M, Zhong S, et al. Dihydroartemisinin ameliorates LPS-induced neuroinflammation by inhibiting the PI3K/AKT pathway. Metab Brain Dis. 2020;35:661–672. doi:10.1007/s11011-020-00533-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11011-020-00533-2</ArticleId>
            <ArticleId IdType="pubmed">32152798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Q, Shi N, Cai C, et al. The role of mitochondria in pyroptosis. Front Cell Dev Biol. 2020;8:630771. doi:10.3389/fcell.2020.630771</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2020.630771</ArticleId>
            <ArticleId IdType="pmc">PMC7859326</ArticleId>
            <ArticleId IdType="pubmed">33553170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, Du J, Li D, et al. Oxidative stress induced pyroptosis leads to osteogenic dysfunction of MG63 cells. J Mol Histol. 2020;51:221–232. doi:10.1007/s10735-020-09874-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10735-020-09874-9</ArticleId>
            <ArticleId IdType="pubmed">32356234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le X, Mu J, Peng W, et al. DNA methylation downregulated ZDHHC1 suppresses tumor growth by altering cellular metabolism and inducing oxidative/ER stress-mediated apoptosis and pyroptosis. Theranostics. 2020;10:9495–9511. doi:10.7150/thno.45631</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/thno.45631</ArticleId>
            <ArticleId IdType="pmc">PMC7449911</ArticleId>
            <ArticleId IdType="pubmed">32863941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Y, Li KS, Liu L, Li SL. MicroRNA132 promotes oxidative stress induced pyroptosis by targeting sirtuin 1 in myocardial ischaemia reperfusion injury. Int J Mol Med. 2020;45:1942–1950. doi:10.3892/ijmm.2020.4557</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ijmm.2020.4557</ArticleId>
            <ArticleId IdType="pubmed">32236570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan X, Zhan E, Yao Y, et al. MiR-599 protects cardiomyocytes against oxidative stress-induced pyroptosis. Biomed Res Int. 2021;2021:3287053. doi:10.1155/2021/3287053</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2021/3287053</ArticleId>
            <ArticleId IdType="pmc">PMC7906806</ArticleId>
            <ArticleId IdType="pubmed">33681353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diao C, Chen Z, Qiu T, et al. Inhibition of PRMT5 attenuates oxidative stress-induced pyroptosis via activation of the Nrf2/HO-1 signal pathway in a mouse model of renal ischemia-reperfusion injury. Oxid Med Cell Longev. 2019;2019:2345658. doi:10.1155/2019/2345658</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/2345658</ArticleId>
            <ArticleId IdType="pmc">PMC6899313</ArticleId>
            <ArticleId IdType="pubmed">31885778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Chen Z, Weng X, et al. Enhancer of zeste homolog 2 modulates oxidative stress-mediated pyroptosis in vitro and in a mouse kidney ischemia-reperfusion injury model. FASEB J. 2020;34:835–852. doi:10.1096/fj.201901816R</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fj.201901816R</ArticleId>
            <ArticleId IdType="pubmed">31914694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes MM, O’Neill LAJ. Metabolic regulation of NLRP3. Immunol Rev. 2018;281:88–98. doi:10.1111/imr.12608</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12608</ArticleId>
            <ArticleId IdType="pubmed">29247992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qiu Z, He Y, Ming H, et al. Lipopolysaccharide (LPS) aggravates high glucose- and hypoxia/reoxygenation-induced injury through activating ROS-dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes. J Diabetes Res. 2019;2019:8151836. doi:10.1155/2019/8151836</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/8151836</ArticleId>
            <ArticleId IdType="pmc">PMC6398034</ArticleId>
            <ArticleId IdType="pubmed">30911553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin Y, Luo T, Weng A, et al. Gallic acid alleviates gouty arthritis by inhibiting NLRP3 inflammasome activation and pyroptosis through enhancing Nrf2 signaling. Front Immunol. 2020;11:580593. doi:10.3389/fimmu.2020.580593</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.580593</ArticleId>
            <ArticleId IdType="pmc">PMC7750458</ArticleId>
            <ArticleId IdType="pubmed">33365024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long Y, Wang X, Youmans DT, Cech TR. How do lncRNAs regulate transcription?
Sci Adv. 2017;3:eaao2110. doi:10.1126/sciadv.aao2110</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.aao2110</ArticleId>
            <ArticleId IdType="pmc">PMC5617379</ArticleId>
            <ArticleId IdType="pubmed">28959731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv Q, Wang Z, Zhong Z, Huang W. Role of long noncoding RNAs in Parkinson’s disease: putative biomarkers and therapeutic targets. Parkinsons Dis. 2020;2020:5374307. doi:10.1155/2020/5374307</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/5374307</ArticleId>
            <ArticleId IdType="pmc">PMC7306067</ArticleId>
            <ArticleId IdType="pubmed">32617144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhattacharjee S, Li J, Dashwood RH. Emerging crosstalk between long non-coding RNAs and Nrf2 signaling. Cancer Lett. 2020;490:154–164. doi:10.1016/j.canlet.2020.07.011</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.canlet.2020.07.011</ArticleId>
            <ArticleId IdType="pubmed">32717274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vuokila N, Aronica E, Korotkov A, et al. Chronic regulation of miR-124-3p in the perilesional cortex after experimental and human TBI. Int J Mol Sci. 2020;21. doi:10.3390/ijms21072418</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms21072418</ArticleId>
            <ArticleId IdType="pmc">PMC7177327</ArticleId>
            <ArticleId IdType="pubmed">32244461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geng L, Liu W, Chen Y. miR-124-3p attenuates MPP (+)-induced neuronal injury by targeting STAT3 in SH-SY5Y cells. Exp Biol Med. 2017;242:1757–1764. doi:10.1177/1535370217734492</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1535370217734492</ArticleId>
            <ArticleId IdType="pmc">PMC5714150</ArticleId>
            <ArticleId IdType="pubmed">28958159</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
